In a surprising turn regarding the shift away from mRNA vaccines, an official overseeing the Make America Health Agent initiative has been dismissed, as reported by Endpoint News in the Pharmaceutical Trade Publications.
Gray Delany, who led the implementation of this initiative at HHS, is no longer in that role. He recently clarified his new status as a “former director of MAHA implementation” on a platform. This decision seems to be a response to ongoing confusion about the Trump administration’s stance on federal mRNA contracts and some tension between the White House and HHS regarding pharmaceutical policies. The report suggested that this chaotic situation prompted Trump advisor Steve Bannon to call for “all-new communications” within HHS.
On August 5th, HHS Secretary Robert F. Kennedy Jr. announced the implementation of the mRNA portfolio from the Biomedical Advanced Research and Development Bureau, part of HHS’s pandemic response effort. He highlighted a shift towards alternatives described as “an evidence-based, ethically grounded solution,” including a new whole virus vaccine. HHS indicated that 22 stalled projects are nearing $500 million in expenditures.
No comments were available from HHS regarding this matter.
President Donald Trump, reflecting on the pivot on August 6, reiterated the importance of seeking new solutions while celebrating Operation Warp Speed, which was the rapid development of Covid-19 vaccines during his first term. This initiative included mRNA products from Moderna and Pfizer, and Trump mentioned an upcoming contract meeting set for August 7th.
“Operation Warp Speed is truly one of the most remarkable achievements in U.S. history,” Trump remarked. “The efficiency of its execution, from development to distribution, was impressive. But we’re now focusing on other answers for different health issues.”
The initial press release highlighted the cancellation of contracts with Moderna and Texas University Medical Branch concerning the H5N1 vaccine. An updated statement mentioned “restructuring” of that project, noting it was partly funded by the Pentagon and outside Kennedy’s purview.
Bannon reached out toEndpoint on Wednesday morning, communicating to Stephanie Spear, the deputy director of HHS, that the announcement wasn’t ideal. He expressed that in the “Trump world,” it signified a complete overhaul was necessary, stating, “Grey Delaney was the right person to handle this.”
At a press gathering on rural health, Kennedy criticized the mRNA vaccine’s effectiveness for respiratory infections, asserting, “We learned during Covid that it’s not effective for such illnesses. It may serve better for cancer.” He added that these vaccines pose challenges that could potentially outweigh benefits for certain conditions.
Kennedy also noted the unpredictable nature of the mRNA vaccine’s effects on the body, mentioning a failure to adequately account for how viruses evolve.
